NGF-Chitosan Combo Repairs Optic Nerve Damage and Restores Vision in Animal Study

Optic nerve damage is a leading cause of irreversible blindness worldwide, with no effective treatments currently available in clinical practice. This groundbreaking study introduces a novel therapeutic approach using nerve growth factor (NGF) combined with chitosan biomaterial to address both primary and secondary nerve degeneration simultaneously.

Researchers created an expanded partial optic nerve transection model to study how NGF-chitosan affects different types of nerve damage. When implanted directly at the injury site, this combination therapy demonstrated remarkable dual benefits: it protected undamaged nerve areas from secondary degeneration while actively promoting regeneration of severed nerve fibers.

The treatment preserved crucial visual functions including pupillary light reflexes and depth perception. Mechanistically, NGF-chitosan enhanced expression of NGF and its receptor TrkA in both optic nerve tissue and retinal ganglion cells. The therapy also reduced harmful microglial activation in injured areas and increased mTOR expression, a key protein involved in cellular growth and repair.

These findings represent a significant advancement in regenerative medicine for vision loss. Unlike current approaches that typically target either neuroprotection or regeneration, this dual-action strategy addresses the complex cascade of events following optic nerve injury. The local delivery method could potentially minimize systemic side effects while maximizing therapeutic benefit at the injury site.

While promising, this research was conducted in animal models, and human clinical trials will be necessary to establish safety and efficacy. The biomaterial approach offers hope for treating various forms of optic neuropathy that currently have limited therapeutic options.